Baxter expands medication delivery business with $338m Prism buy
This article was originally published in Clinica
Executive Summary
In a move to bulk up its medical delivery offerings, Baxter has definitively agreed to acquire Prism Pharmaceuticals, a privately-held developer of an FDA-approved antiarrhythmic agent, for up to $338m.